In this issue of Ceil, we take the unusual step of publishing two articles each of which reports the identification of a different gene in the appropriate chromosomal region associated with the human disease of spinal muscular atrophy (SMA). Each paper individually meets the standard for publication in providing adequate evidence to identify systematic changes in the gene in patients with the disease but not in normal people, but the two groups have identified unrelated genes, called SMN and NAIP.
SMA is a relatively common recessive autosomal disease, affecting -1 in 6000 births, and is one of the most common genetic causes of death in childhood. Three clinical types of the disease (I, II, and III) are distinguished by the (decreasing) severity of the symptoms. The common cause is depletion of motor neurons in the spinal cord, resulting in muscular atrophy with consequent paralysis of limb and trunk. All three types of SMA map to chromosome region 5q11.2-q13.3, and several research groups have been engaged for some years in constructing molecular maps of this region in order to identify the causal locus.
The search for SMA has been complicated by the instability of this chromosomal region; it has many repetitive sequence elements that often cause instability in cloned sequences. It has several classes of expressed pseudogenes, which have an interrupted organization and generate transcripts that are spliced to give mRNA-like molecules that do not give functional products. This complicates attempts to identify the gene(s) for SMA, because lOOkb probes for coding regions react with the pseudogenes and their transcripts as well as with the sequences of any authentic gene.
SMN Lies in a Large Inverted Duplication
The report from Lefebvre et al. (1995) utilizes CEPH YAC libraries prepared from a single human donor. The YACs were mapped by PFGE of restriction fragments, and the locations of polymorphic microsatellite markers on these YACs were determined by PCR screening. The map shown in Figure 1 has an inverted duplication of -500 kb. The two repeats are distinguished by the different sizes of restriction fragments obtained with Hindlll; the centromeric repeat has a fragments of 12 kb and 3.7 kb, while the telomeric repeat has fragments of 11 kb and 3.7 kb. Both sets of fragments are present in normal individuals and also in a monochromosomal hybrid cell line, suggesting that they represent a bona fide duplication and not allelic polymorphism. Confirming the instability of this chromosomal region, PFGE analysis of large restriction fragments shows extensive polymorphism in the normal as well as the patient population.
Patients with type I or type II SMA (and more rarely with type III SMA) have deletions in the telomeric repeating unit that extend from the microsatellite marker C272 to the 11 kb He3 fragment. Screening of fetal brain cDNAs identified a clone (BCD541) that corresponds to a widely expressed transcription unit of 1.7 kb. This clone identifies a gene, called SMN, that has 8 exons extending over -20 kb. There is a copy of the gene in both the telomeric and centromeric repeating units, and the copies are virtually identical; 5 base substitutions have been identified, 2 of which lie in exons 7 and 8, and none of which affects the coding of the protein product. SSCP analysis of the regions containing the sites that differ therefore allows the centromeric and telomeric copies to be distinguished in exons 7 and 8. When 229 patients were screened for the presence of exons 7 and 8, most (213) lacked the telomeric copy of both exons, and 13 lacked the telomeric copy of exon 7 but retained exon 8. This indicates that the vast majority of patients have a deletion of at least the 3' end of the gene (and possibly of the entire gene), and a small number have a truncation of the gene from the 5' end. This suggests that the right chromosomal region has been identified, but does not equate the disease with the gene, since the deletion is not demonstrated to be confined exclusively within it. However, the remaining 3 patients satisfy this standard. Each has a different mutation. One has a deletion at the splice acceptor site of intron 6, and another has a deletion at the splice donor site of intron 7; both of these patients have only one (mutant) allele, the other allele being entirely absent. Their inheritance of these alleles can be traced from heterozygous parents. It is fortunate (and perhaps surprising) that the individual mutations occurred within the regions that can be distinguished between the telomeric and centromeric copies of the gene. The third patient has two coding sequences for exon 6, one carrying a mutation that converts tyrosine to cysteine, leading to the surmise that the mutation lies in the telomeric copy. None of the mutations found in these three patients occurs in the normal population, suggesting that they are causal for the disease, and not the result of a polymorphism.
NAIP Has Many Deleted Pseudogenes
A similar approach in covering the region has been followed by Roy et al. (1995) , who first developed a YAC contig that uses YACs derived from three libraries, and then moved to a PAC (P1 artificial chromosome) contig. They have mapped tandem repeats mostly based on highly polymorphic CA, tracts; their map is shown in Figure  2 . They also screened a fetal brain cDNA library with a PAC that contained the polymorphic markers showing the greatest association with the disease, and identified a gene, called NAIP, of at least 16 exons dispersed over 60 kb. When blots of BamHI-digested genomic DNA are probed with exons 2-10 of NAIP, three bands are found. A band of 14.5 kb represents two equally sized fragments that represent the central 29 kb of the gene. A band of 23 kb results from a 6 kb deletion that removes exons 5-6 and the central BamH1 site. A band of 9.6 kb represents a gene that has lost its 5' end upstream of exon 7. The 9.6 and 23 kb bands occur at variable dosage in the general population, suggesting that they represent pseudogenes that vary in number between individuals. In fact, a cDNA library from normal fetal brain tissue contains a large number of deleted variants, suggesting that the pseudogenes are transcribed.
Probing genomic DNA for exons 5-6 shows that all normal people display a 9.4 kb Ec~)R1 band representing the intact gene. 45% of SMA type I individuals and 18% of SMA type II or III individuals have a homozygous deletion A PAC contig for the region associated with SMA has two copies of the NAIP gene; ~NAIP is a deleted copy, and NAIP is a copy that has markers associated with the disease. These are shown as *NAIP and NAIP, respectively, on the map of Roy et al. of these exons, implying an association of this region with the disease. In one pedigree, parents who displayed all three BamH1 bands had normal children, all of whom retained a 14.5 kb band, and had children with the disease, all of whom lacked the 14.5 kb band. Thus inheritance in homozygous state of the deleted gene shows the expected correlation with the disease. However, a general examination of the genotypes of parents whose children showed type I SMA identified three cases in which there appeared to be homozygous loss of exons 5-6 without phenotypic consequence, casting some doubt on whether this event alone is sufficient to cause the disease. This requires the introduction of arguments for an effect of penetrance, or involvement of additional loci.
The correlation between NAIP and SMA was taken further by examining RNA from patients and normal people. Using primers for sequences in exon 10 or exon 13, cDNAs of the expected sizes could be amplified from all normal samples. In most cases, material could not be amplified from patients, suggesting a deficiency of expression of NAIP. In the exceptional cases in which cDNA was obtained from patients, sequencing of the products showed aberrations in every case. None of these changes could be detected in normal people. However, given the presence of multiple pseudogenes, this does not necessarily imply that the NAIP gene carried the observed mutations in each patient; it could instead be the case that the NAIP gene has been deleted, and the amplification products represent expression of pseudogenes, which were not detected in normal samples because they represented a small proportion of transcripts relative to the wild-type gene. It is therefore clear that deletion of NAIP is associated with the disease, but there is not yet a hereditary or sporadic demonstration of a change that can be shown to be confined only to the gene itself.
Another cDNA that detects deletions in SMA type I patients has been identified by Thompson et al. (1995) . Originally identified by an exon amplification technique, clone XS2G3 detects nonallelic Hindlll fragments of 17, 12, and 4 kb. The 12 kb fragment is homozygously deleted in 17/ 29 type I SMA patients, in only 1 type II patient, and not in type III patients; however, it is also absent from 2/235 unaffected people, both carriers. This again suggests that type I SMA is caused by larger changes than type II or type Ill, but it remains to be seen whether XS2G3 identifies sequences in the causal gene. XS2G3 detects RNAs of various sizes. The exon that was amplified is part of a 3' UTR, and has the curious feature that it is complementary to part of exon 6 of NAIP. This reinforces the view of this region as highly variable.
The presence of many pseudogenes in the SMA region itself poses a problem for validating any particular gene as a bona fide functional locus. Many of the pseudogenes are expressed at higher levels in brain than in other tissues (Bruno et al., 1994) . (The number and variety of expressed pseudogenes brings to mind the old data that the complexity of RNA expressed in the brain is an order of magnitude greater than other tissues.) These pseudogenes may have exons containing interesting combinations of protein motifs. How is one to tell whether any particular combination of exons found in the genome, and corresponding to various RNA products, represents a functional locus? Some conviction is lent by characterizing the individual exons, but a decisive demonstration may require the cloning of a cDNA that actually represents an RNA in which all of the exons are juxtaposed, and can generate a functional protein product.
Reconciling the Two Maps
There seems no doubt that the region containing SMN and NAIP carries the mutations that cause SMA. Strong linkage disequilibrium with the SMA phenotype was found for markers within both genes (this means that in populations the marker is tightly linked to the disease; it is an equivalent measure to assessing linkage as the result of a genetic cross). The genes in fact are adjacent (or to be more precise, certain copies of each gene are adjacent). Deletions that affect these genes are very strongly associated with the disease, it is unlikely that the disease is caused by mutations that lie outside the -500 kb region that contains the adjacent SMN and NAIP genes, although one would like to see a transcript map to determine what other genes lie in this region; and there remains the possibility that other genes in the immediate vicinity contribute to the disease.
One urgent priority is to reconcile the maps obtained by the two groups. However, this region of the genome is highly polymorphic, and is replete with duplications and deletions. Only a few markers are common to both groups, but because of the repeated copies, it is difficult to make direct comparisons (note the locations of the markers CMS, C161/CATT1, and C272 on the maps of Figures 1  and 2 ). Each group has identified regions corresponding to the gene identified by the other group, but has not directly shown which of these regions corresponds to the copy implicated in disease.
Although both groups show two copies of each gene, these do not correspond directly, and the region characterized in detail by Roy et al. appears Thus it is difficult to know whether corresponding copies of the gene are being compared between the two maps. Of the several possibilities for reconciling the maps, each has its own problems. Suppose first of all that the copies identified with disease must lie at the same location. This would give the alignment of Figure 3A , but this places the SMN and NAIP genes in opposite orientation with regards to the centromere. If we conserve the orientation in which SMN is centromeric to NAIP, there are two possibilities. Figure 3B shows that the map of Roy et al. could be aligned with the centromeric repeating unit of Lefebvre et al. The problem here is that disease is now associated with the centromeric repeat for Roy et al. and with the telomeric repeat for Lefebvre et al. Figure 3C shows an alignment in which the other copy of SMN of Roy et al. is aligned with the disease copy of Lefebvre et al., which would mean that the SMN and NAIP loci associated with disease would be separated by one of the NAIP pseudogenes, posing a problem with the linkage disequilibrium mapping.
We need to know whether the inverted duplication is general in the population (as suggested by the results of Lefebvre et al.) If it is, one of the copies of NAIP shown on the map of Figure 1 must lack exons 5-6, since Roy et al. show that there is only one NAIP locus with these exons. In fact, there appear to be deletions in the distal end of the telomeric repeating unit that could well include NAIP. If the inverted duplication is not common in the population, we need to explain its occurrence in the library of Lefebvre et al., and to determine its relationship to the cause of disease. Certainly the map would be much simpler to analyze if there were only one repeating unit. Most contigs for markers linked to SMA phenotype appear to identify a region that corresponds to only a single (nonduplicated) unit, but on the other hand, it is clear that duplications and deletions are frequent (Carpten et al., 1994; Francis et al., 1993; Kleyn et al., 1993) .
Criteria for Assigning a Gene to the Disease
The nature of the sequence of a gene does not necessarily provide information about its involvement in a disease. SMN codes for a small protein (294 amino acids) with no relations in the data base. NAIP codes for a large protein (1232 amino acids) and has a domain that shows homology with the baculoviral inhibitor of apoptosis. Loss of antiapoptotic function would be consistent with the phenotype of swelling and lysis of motor neurons that typifies SMA. The expression pattern offers no help, because both genes are quite broadly expressed. No sequence relationship between the genes is evident.
If the disease is associated with this confined region, how are we to distinguish whether it is caused by one of the genes (in which case the mutations in the other must be adventitious) or whether both are involved? The usual assumption in seeking the genetic cause for a disease that behaves as a Mendelian trait and maps to a defined chromosomal region is that a single gene will be responsible. The standard for proving the case is taken to be the presence in patients but not in normal people of changes that are confined to that gene alone (that is, comprising internal deletions or point mutations).
Lefebvre et al. have met this standard, but there is one feature that causes disquiet: the second (nonallelic) copy of the gene apparently has no inactivating mutations. That copy has a pattern of alternative splicing that generates transcripts lacking exon 7, but it also generates full-length transcripts, which presumably are functional. A reasonable expectation in this situation is that the nonallelic genes should be redundant and that mutation in either should not cause disease. If reduction of dosage were responsible for the disease, there would be no reason for the loss in patients to be confined to one copy rather than the other. However, 10% of normal people lack the centromeric copy of SMN, implying that its deletion has no phenotypic effect, and that there may be a functional difference between the two copies of the gene.
Roy et al. have the advantage of finding only a single functional locus for NAIP, and they show strong association between deletion of that locus and the disease. The sequence of the gene offers a connection with the disease phenotype. However, it remains possible that all the mutations seen in patients extend beyond the gene into neighboring territory. Because of the existence of the pseudogenes, it is difficult to determine with individual exonic probes whether patients who (for example) have lost exons 5-6 have done so as the result of internal deletion or have lost the entire NAIP locus.
The existence of multiple pseudogenes for NAIP that have large deletions or truncations suggests that unequal crossing over between nonallelic copies could be one of the causes of instability in this region. Any such event would delete material between the sites of recombination, making it plausible that more than one gene may be affected, so that most of the observed deletions are not informative. Clearly it becomes important to map the ends of the deletions in order to determine whether only one or more genes are lost, and whether there is a common denominator that relates to loss of SMN, NAIP, or other genes in the various types of SMA.
As a note of caution, there is a precedent for the occurrence of mutations that map to the right region in patients, but do not in fact identify the causal locus: the gene MCC is located in the chromosomal region associated with APC (adenomatous polyposis coil) and was identified as a candidate for the cause of the disease on the basis of accumulation of mutations in tumors in sporadic cases (Kinzler et al., 1991) . However, it turns out that the authentic APC gene lies 150 kb away, as identified by the occurrence of germline mutations in familial cases (Joslyn et al., 1991; Nishisho et al., 1991) . Of course, the misleading mutations occurred in somatic tissue, and.there is so far no comparable case with germline mutations.
Is it possible that both genes are associated with the disease? It is extremely rare in higher eucaryotes to find unrelated neighboring genes that code for proteins that function in the same pathway. One case is the example of RAG1 and RAG2, both of which are needed for recombination of immunoglobulin genes (Oettinger et al., 1990) ; deletion of either of the adjacent genes has the same effect on the phenotype. Some features of SMA could be interpreted in terms of such a model. The varying types of the disease could be interpreted in terms of different causal loci or in terms of mutations of varying severity in a single locus. The latter explanation became favored as the result of demonstrations that different types of the disease map to the same chromosomal locus (Melki et al., 1990) . However, this would not distinguish the involvement of one locus from a role for multiple but adjacent loci. Almost all patients of SMA types I and II display deletions in SMN; patients with type III SMA do not have gross deletions, but have (presumably nonallelic) copies of the cBCD541 sequence, which Lefebvre et al. propose could be explained by a gene conversion of the telomeric gene to the sequence of the centromeric gene. In terms of large scale changes, deletion of NAIP is less common in type II and Ill than in type I SMA.
These possibilities make it difficult to establish the standard for proof. There have been cases in which the conventional criteria could not apply, most notably that of Charcot-Marie-Tooth disease, which results from duplication of a locus (Lupski et al., 1991) , it therefore being impossibie to demand a demonstration of internal mutations. The standard would also need to be different if mutations in either of two genes could cause disease, or if mutations in two genes were both necessary for disease. In the first case, the problem arises when there is no evident genetic heterogeneity and the two genes are in close proximity, because either gene individually should apparently be excluded by patients that lack mutations in it. In the second case, all patients should have long deletions or multiple independent mutations. The next step to resolve the situation with regards to SMA is to reconcile the two maps and to determine whether there is a systematic association of only one or both genes with the disease. In the long term, it may be necessary to move to a mouse model, by disrupting the appropriate homologs in isogenic backgrounds, to prove cause and effect. At all events, SMA promises to be one of the most interesting traits to characterize at the molecular level.
